Atorvastatin: safety and tolerability

被引:68
作者
Athyros, Vasilios G. [1 ]
Tziomalos, Konstantinos [2 ]
Karagiannis, Asterios [1 ]
Mikhailidis, Dimitri P. [3 ]
机构
[1] Aristotle Univ Thessaloniki, Sch Med, Hippokrat Hosp, Propedeut Dept Internal Med 2, Thessaloniki 55132, Greece
[2] Aristotle Univ Thessaloniki, Sch Med, AHEPA Hosp, Propedeut Dept Internal Med 1, Thessaloniki 55132, Greece
[3] UCL, Sch Med, Dept Clin Biochem, Vasc Prevent Clin, London NW3 2QG, England
关键词
atorvastatin; drug combinations; liver enzyme elevation; myositis; safety; tolerability; CORONARY-HEART-DISEASE; COA REDUCTASE INHIBITORS; HIGH-DOSE ATORVASTATIN; RANDOMIZED CONTROLLED-TRIAL; STATIN-INDUCED MYOPATHY; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR END-POINTS; TYPE-2; DIABETES-MELLITUS; CHRONIC KIDNEY-DISEASE; LIPID-LOWERING DRUGS;
D O I
10.1517/14740338.2010.495385
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Importance of the field: Atorvastatin is the most widely used statin administered in a variety of settings, including primary and secondary prevention of cardiovascular events, in the elderly, in patients with chronic kidney disease and in diabetic patients. Therefore, the safety and tolerability of atorvastatin is of paramount importance. Areas covered in this review: We searched MEDLINE for literature published between 1997 and 2010 on the safety and tolerability of atorvastatin. We retrieved data from randomized controlled trials, meta-analyses, post-marketing studies, reports to regulatory bodies and case reports of rare adverse events. What the reader will gain: The reader will gain insight into the incidence, severity, prevention and management of the major adverse effects of atorvastatin (i.e., liver function abnormalities and muscle-related side effects) overall and in special populations. Take home message: The existing data suggest that atorvastatin is generally well tolerated across the range of its therapeutic dosage (10 - 80 mg/day).
引用
收藏
页码:667 / 674
页数:8
相关论文
共 71 条
[1]
Update in Vitamin D [J].
Adams, John S. ;
Hewison, Martin .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (02) :471-478
[2]
Low serum 25 (OH) vitamin D levels (<32 ng/mL) are associated with reversible myositis-myalgia in statin-treated patients [J].
Ahmed, Waqas ;
Khan, Naseer ;
Glueck, Charles J. ;
Pandey, Suman ;
Wang, Ping ;
Goldenberg, Naila ;
Uppal, Muhammad ;
Khanal, Suraj .
TRANSLATIONAL RESEARCH, 2009, 153 (01) :11-16
[3]
The safety of rosuvastatin as used in common clinical practice - A postmarketing analysis [J].
Alsheikh-Ali, AA ;
Ambrose, MS ;
Kuvin, JT ;
Karas, RH .
CIRCULATION, 2005, 111 (23) :3051-3057
[4]
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system) [J].
Alsheikh-Ali, Alawi A. ;
Karas, Richard H. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (03) :379-381
[5]
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[6]
Prescription of statins to dyslipidemic patients affected by liver diseases: a subtle balance between risks and benefits [J].
Anfossi, G ;
Massucco, P ;
Bonomo, K ;
Trovati, M .
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2004, 14 (04) :215-224
[7]
[Anonymous], MED PROD SAF INF
[8]
Atorvastatin - A safety and tolerability profile [J].
Arca, Marcello .
DRUGS, 2007, 67 (Suppl 1) :63-69
[9]
The safety of statins in clinical practice [J].
Armitage, Jane .
LANCET, 2007, 370 (9601) :1781-1790
[10]
Statin-induced myopathy: The two faces of Janus [J].
Arora, Rohit ;
Liebo, Max ;
Maldonado, Frank .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2006, 11 (02) :105-112